Skip to main content

Cushing's Syndrome News

Related terms: Cushing's Syndrome, ectopic, Cushing's Syndrome, exogenous, Cushing's Disease

FDA Grants Isturisa (osilodrostat) Expanded Indication for the Treatment of Endogenous Hypercortisolemia in Patients with Cushing’s Syndrome

Milan, Italy and Bridgewater, NJ, April 16, 2025 – Today Recordati announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Isturisa (...

FDA Approves Recorlev (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

CHICAGO--(BUSINESS WIRE)--Dec. 30, 2021-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in...

FDA Approves Isturisa (osilodrostat) for the Treatment of Cushing’s Disease

March 06, 2020 – The U.S. Food and Drug Administration today approved Isturisa (osilodrostat) oral tablets for adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have ...

FDA Approves Signifor, a New Orphan Drug for Cushing’s Disease

December 14, 2012 – The U.S. Food and Drug Administration today approved Signifor (pasireotide diaspartate) injection for the treatment of Cushing’s disease patients who cannot be helped through s...

FDA Approves Korlym for Patients with Endogenous Cushing's Syndrome

FRIDAY, February 17, 2012 – Today, Korlym (mifepristone) was approved by the U.S. Food and Drug Administration to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing’s s...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

dexamethasone, cyproheptadine